Moreover, the HIMALAYA trial (NCT03298451) is a multicentre phase III trial exploring the safety and efficacy of Durvalumab (a PD‐L1 inhibitor) both as monotherapy and in combination with Tremelimumab (a CTLA‐4 inhibitor) versus Sorafenib in patients with advanced HCC who have not received prior systemic therapy and are also not eligible for locoregional therapy.85 The gene discussed is CTLA4; the disease is hepatocellular carcinoma.